| scholarly article | Q13442814 |
| P2093 | author name string | Stephane Mouly | |
| Guy Simoneau | |||
| Laurent Becquemont | |||
| Alan Swaisland | |||
| Celine Verstuyft | |||
| Ilana Peretti | |||
| Jean Francois Bergmann | |||
| Nathalie Rizzo-Padoin | |||
| Robert Wortelboer | |||
| Stephanie Chhun | |||
| P2860 | cites work | The role of ABC transporters in drug resistance, metabolism and toxicity | Q28283237 |
| Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins | Q31945488 | ||
| The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity | Q33256349 | ||
| Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males | Q33981408 | ||
| Noninvasive tests of CYP3A enzymes | Q34059919 | ||
| Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol | Q34452644 | ||
| Expression of a multidrug-resistance gene in human tumors and tissues | Q34586576 | ||
| Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo | Q35113118 | ||
| Interactions between antiepileptic and chemotherapeutic drugs | Q35172242 | ||
| Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences | Q35238375 | ||
| Pharmacokinetic evaluation of gefitinib when administered with chemotherapy | Q35594728 | ||
| Gefitinib, a novel, orally administered agent for the treatment of cancer | Q35739717 | ||
| MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males | Q35804210 | ||
| Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. | Q35827661 | ||
| Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy | Q35842908 | ||
| Drug-drug interactions in oncology: why are they important and can they be minimized? | Q36125253 | ||
| Pharmacogenetic pathway analysis of docetaxel elimination. | Q36182023 | ||
| The human intestinal cytochrome P450 "pie". | Q36420382 | ||
| ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. | Q36592129 | ||
| Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs | Q39983172 | ||
| Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. | Q40168706 | ||
| Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. | Q40310402 | ||
| Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 | ||
| Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. | Q40449494 | ||
| High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter | Q40553425 | ||
| The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 | ||
| Cytochrome P450 proteins and potential utilization in biodegradation | Q40948757 | ||
| Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. | Q43738208 | ||
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study | Q43865209 | ||
| A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials | Q44026405 | ||
| Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans | Q44085569 | ||
| Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients | Q44486217 | ||
| United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets | Q44772598 | ||
| Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. | Q46375109 | ||
| Effects of uptake and efflux transporter inhibition on erythromycin breath test results | Q46375419 | ||
| Cytochrome P450-dependent metabolism of gefitinib | Q46402129 | ||
| In vitro metabolism of gefitinib in human liver microsomes | Q46413695 | ||
| Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue | Q46500133 | ||
| Single-dose clinical pharmacokinetic studies of gefitinib | Q46758727 | ||
| Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma | Q46856639 | ||
| Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients | Q46963924 | ||
| CYP3A4 and the erythromycin breath test | Q47722007 | ||
| Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics | Q48695639 | ||
| Interaction between grapefruit juice and midazolam in humans* | Q51599931 | ||
| Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. | Q51623373 | ||
| PCR-based genotyping for duplicated and deleted CYP2D6 genes | Q71690601 | ||
| Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction | Q71895507 | ||
| P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients | Q72712583 | ||
| Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia | Q73171655 | ||
| Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test | Q73369035 | ||
| The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance | Q73707339 | ||
| Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity | Q73907168 | ||
| Grapefruit juice increases oral nimodipine bioavailability | Q74485622 | ||
| Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans | Q77360264 | ||
| CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors | Q79407997 | ||
| Pharmacogenetics of ABCG2 and adverse reactions to gefitinib | Q79407999 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breathing | Q9530 |
| P304 | page(s) | 226-237 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers | |
| P478 | volume | 68 |
| Q37873453 | Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. |
| Q37399419 | Communicating about potential drug harms: safety implications for patients |
| Q92354500 | Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer |
| Q38225680 | Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective |
| Q51527303 | Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. |
| Q91792958 | Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study |
| Q35023711 | Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. |
| Q36339094 | OATP1B1 polymorphism as a determinant of erythromycin disposition |
| Q36530038 | Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer |
| Q36365500 | Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. |
| Q39031326 | Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. |
| Q84527412 | Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects |
Search more.